AGR:LSE-Assura Plc (GBX)

COMMON STOCK | REIT—Healthcare Facilities | LSE

Last Closing Price

GBX 77.40

Change

-0.30 (-0.39)%

Market Cap

GBX 2.06B

Volume

3.60M

Average Target Price

GBX 84.67 (+9.39%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create outstanding spaces for health services in our communities. At 31 March 2020, Assura's property portfolio was valued at £2,139 million.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-08 )

Largest Industry Peers for REIT—Healthcare Facilities

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PHP:LSE Primary Health Properties PLC

-0.40 (-0.26%)

GBX1.86B N/A N/A
THRL:LSE Target Healthcare REIT plc

+0.80 (+0.75%)

GBX0.51B 13.98 26.25
IHR:LSE Impact Healthcare REIT plc

+1.00 (+1.03%)

GBX0.30B 9.32 N/A

ETFs Containing AGR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (REIT—Healthcare Facilities)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.51% 100% A+ 71% C-
Dividend Return 0.91% 67% D+ 34% F
Total Return 0.40% 100% A+ 71% C-
Trailing 12 Months  
Capital Gain 19.81% 100% A+ 87% B+
Dividend Return 3.24% 75% C 76% C
Total Return 23.05% 100% A+ 86% B
Trailing 5 Years  
Capital Gain 45.77% 67% D+ 76% C
Dividend Return 22.31% 100% A+ 81% B-
Total Return 68.08% 67% D+ 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 9.12% 50% F 54% F
Dividend Return 4.31% 100% A+ 82% B-
Total Return 13.43% 50% F 66% D
Risk Return Profile  
Volatility (Standard Deviation) 15.20% 50% F 62% D-
Risk Adjusted Return 88.39% 50% F 76% C
Market Capitalization 2.06B 100% A+ 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(REIT—Healthcare Facilities)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.94 33% F 28% F
Price/Book Ratio 1.61 25% F 35% F
Price / Cash Flow Ratio 31.05 25% F 11% F
EV/EBITDA 28.28 50% F 13% F
Management Effectiveness  
Return on Equity 6.11% 50% F 55% F
Return on Invested Capital 4.56% 33% F 52% F
Return on Assets 2.76% 25% F 53% F
Debt to Equity Ratio 63.77% 67% D+ 28% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.10 75% C 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.